Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) EV-to-EBITDA : 0.00 (As of May. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cancer Prevention Pharmaceuticals's enterprise value is $0.00 Mil. Cancer Prevention Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.97 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

CPP's EV-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 14.53
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Cancer Prevention Pharmaceuticals's stock price is $25.91. Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.970. Therefore, Cancer Prevention Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Cancer Prevention Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals EV-to-EBITDA Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

EV-to-EBITDA

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
EV-to-EBITDA	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Cancer Prevention Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Prevention Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's EV-to-EBITDA falls into.

Cancer Prevention Pharmaceuticals EV-to-EBITDA Calculation

Cancer Prevention Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.000	/	-3.972
	=	0.00

Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.97 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) EV-to-EBITDA Explanation

Cancer Prevention Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	25.91	/	-0.970
	=	At Loss

Cancer Prevention Pharmaceuticals's share price for today is $25.91.
Cancer Prevention Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.970.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Cancer Prevention Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.